NCT01201915View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Basal Cell Carcinoma

Interventions

DRUG

Vismodegib

Vismodegib was supplied in gelatin capsules.

Trial Locations (12)

19111

Philadelphia

30005

Alpharetta

33716

St. Petersburg

38134

Bartlett

40217

Louisville

53705

Madison

60611

Chicago

77030

Houston

85259

Scottsdale

90045

Los Angeles

92117

San Diego

94063

Redwood City

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY